by Stephen Levin
While the emergence of so-called quality-of-life (QOL) medicine has had a greater impact in pharmaceuticals, the medical device industry has...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Satiety: Treating Obesity Beyond Quality of Life
Obesity is no longer merely a lifestyle-related condition; it's a worldwide epidemic with life-threatening consequences. Satiety is developing a device-based alternative to surgery that could expand the market for both physicians and patients.
More from Innovation
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
• By
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
More from In Vivo
• By
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
• By
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.